sct200
mAbexperimental
Clinical trial activity
9 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02211443)
Timeline
Indications
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- sct200
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05552807 | Phase 1 | Jun 15, 2022 | Huazhong University of Science and Technology, Sinocelltech Ltd. |
| NCT04229537 | Phase 1 | Mar 1, 2020 | Sinocelltech Ltd., Tianjin Medical University |
| NCT03808701 | Phase 1 | Mar 31, 2019 | Jilin Provincial Tumor Hospital, Sinocelltech Ltd. |
| NCT03874741 | Phase 2 | Mar 31, 2019 | Chinese Academy of Medical Sciences, Sinocelltech Ltd. |
| NCT03692520 | Phase 1 | Sep 30, 2018 | People's Liberation Army of China, Sinocelltech Ltd. |
| NCT03692689 | Phase 2 | Jul 20, 2018 | Harbin Medical University, Sinocelltech Ltd. |
| NCT03817567 | Phase 1/Phase 2 (Phase 2) | Jul 17, 2018 | Sinocelltech Ltd., Tianjin Medical University |
| NCT03405272 | Phase 2 | Feb 12, 2018 | Chinese Academy of Medical Sciences, Sinocelltech Ltd. |
| NCT02211443 | Phase 1 | Jan 1, 2015 | Sinocelltech Ltd. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sinocelltech Ltd. | For profit | 9 | 9 | 2 | 2015 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 1 | 2018 |
| Tianjin Medical University | Academic/Hospital | 2 | 0 | 2 | 2018 |
| Harbin Medical University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Jilin Provincial Tumor Hospital | Academic/Hospital | 1 | 0 | 1 | 2019 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2018 |
7 organizations
Page 1 / 1